Accepted Abstracts for oral presentation

Importance of the receptor binding surveillance to detect the jumping of the host range of the highly pathogenic bird influenza virus (H5N1) into humans
Yasuo Suzuki, College of life and health sciences, Chubu University, Aichi, Japan
Pathogenesis of H5N1 a/vietnam/1203/04 in a mouse infection model
James Long, Battelle medical research & evaluation facility, Columbus, USA
Distinct inhibition patterns of influenza a virus between the two most frequent alleles at the porcine MX1 locus
Mélanie Palm, Faculty of Veterinary Medicine, University of Liège, Belgium
Clinical and laboratory comparison of human infections with dengue, influenza or avian influenza a (H5N1) viruses in Indonesia
Herman Kosasih, Naval Medical Research Unit #2 (NAMRU-2) Jakarta, Indonesia
Increased sensitivity to Oseltamivir of the neuraminidase of recent Influenza A (H5N1) viruses
Marie Anne Rameix-Welti, Unité de Génétique Moléculaire des Virus Respiratoires, Institut Pasteur, Paris, France
An alternative neutralization assay for H5N1 influenza a virus using retroviral pseudotypes
Nigel Temperton, MRC/UCL Centre for Medical Molecular Virology, University College London, London, United Kingdom
Development of a real-time PCR assay for the detection of human influenza a (H5N1) virus and sequence comparison of three avian influenza a (H5N1) detected in Switzerland
Yves Thomas National Centre of Influenza, University Hospital of Geneva, Geneva, Switzerland
The NA-Starâ influenza neuraminidase inhibitor resistance detection kit: chemiluminescence assay for detection and quantification of influenza neuraminidase activity
Corinne Olesen, Applied Biosystems, Bedford, USA
A new approach for an influenza virus live vaccine by modification of the cleavage site of the haemagglutinin by reverse genetics
Juergen Stech, Institute of Virology, University Hospital Giessen-Marburg, Germany
Development of vaccines against pandemic influenza : Safety, immunogenicity and prospects of an inactivated split-virion H5N1 influenza vaccine
Dr Agnes Hoffenbach, Influenza Franchise Program Leader, Sanofi Pasteur, Marcy l'Etoile, France
Respiratory protection against avian influenza
Pierre Jean Messier, Triosyn Corporation , USA
Subtype-diverse inactivation of influenza A viruses including H5N1 with an extract of Trifolium species and pomegranate juice
Girish Kotwal, Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town School of Medicine, Cape Town, South Africa
Detection of avian influenza A/H5 viral isolates with highly sensitive, specific and inclusive real-time RT-PCR assays
Olga Petrauskene, Applied Biosystems, Foster City, USA
Novel antivirals targeting influenza virus-specific membrane rafts
Cornelia Schroeder, Jado Technologies, Dresden, Germany